Sebastian Kreiter
Executive Advisory Board
BioNTech
Germany
Biography
Sebastian Kreiter developed the fundamentals of the Ribological® RNA vaccine platform under the guidance of Ugur Sahin. They have been working together since 2001. He continues to focus on innovative concepts for the Ribological® immunotherapy program. Sebastian is also heading the Department for Immune Therapy Development at TRON gGmbH, a non-profit institute in Mainz. Furthermore he acts as the Executive Director of Science and board member for the Association for Cancer Immunotherapy (CIMT) and has co-authored many publications in peer-reviewed journals investigating the preclinical development of cancer vaccinations.
Research Interest
Oncology
